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Background: Plant flavonoids are emerging as potent therapeutic drugs effective against a wide range of aging
diseases particularly bone metabolic disorders. Morin (3,5,7,20,40-pentahydroxyflavone), a member of flavonols, is an
important bioactive compound by interacting with nucleic acids, enzymes and protein. The present study was
designed to investigate the putative beneficial effect of morin on diabetic osteopenia in rats.
Methods: Streptozotocin (STZ)-induced diabetic model was used by considering 300 mg/dl fasting glucose level as
diabetic. Morin (15 and 30 mg/kg) was treated for five consecutive weeks to diabetic rats. Serum levels of glucose,
insulin, deoxypyridinoline cross links (DPD), osteocalcin (OC), bone specific alkaline phosphatase (BALP), telopeptides
of collagen type I (CTX), interleukin 1 beta (IL-1β), interleukin 6 (IL-6), tumor necrosis factor alpha (TNF-α),
thiobarbituric acid reactive substance (TBARS) and reduced glutathione (GSH) were estimated. Femoral bones were
taken for micro CT scan to measure trabecular bone mineral density (BMD) and other morphometric parameters.
Results: Significant bone loss was documented as the level of bone turnover parameters including DPD, OC, BALP
and CTX were increased in serum of diabetic rats. Morin treatment significantly attenuated these elevated levels.
Bone micro-CT scan of diabetic rats showed a significant impairment in trabecular bone microarchitecture, density
and other morphometric parameters. These impairments were significantly ameliorated by morin administration.
Serum levels of glucose, TBARS, IL-1β, IL-6 and TNF-α were significantly elevated, while the level of insulin and GSH
was decreased in diabetic rats. These serum changes in diabetic rats were bring back to normal values after 5
weeks morin treatment.
Conclusion: These findings revealed the protective effect of morin against diabetic induced osteopenia. We
believed that this effect is through its both the anti-inflammatory and antioxidant properties.
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Diabetes mellitus is a group of frequently encountered
clinical metabolic problems. It is characterized by hyper-
glycemia due to shortage in the secretion and/or actions
of insulin. Diabetic complications are many including
nephropathy, neuropathy, retinopathy and cardiovascu-
lar diseases, as well as alterations of bone and mineral
metabolism [1]. Diabetic associated osteopenia results in
both increased risk of bone fracture and delay in the
process of bone fractures healing, which affect the qual-
ity of life in diabetic patients [2,3]. Optimal therapies for* Correspondence: rejaie@hotmail.com
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distribution, and reproduction in any mediumsuch disorder are few. Therefore, controlling its develop-
ment is of great significance for patients with diabetes.
Mechanisms responsible for diabetic osteopenia have
not been clearly identified thus far. Oxidative stress
has been suggested as one of the contributing factors in
diabetic osteopenia [4]. Bai et al. [5] reported that, osteo-
blast or bone forming cells, differentiation can be inhib-
ited by oxidative stress. It also believed that oxidative
stress induces osteoblast insults and apoptosis [2].
Hyperglycemia itself showed damaging effect on osteo-
blast differentiation, bone formation and mineralization
[6]. Furthermore, oxidative stress along with hypergly-
cemia are sources for the generation of free radicals and
reactive oxygen species (ROS) that can disrupt cellular
function and damage proteins, lipids and DNA [7].entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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significantly influence the incidence and development of
diabetic osteopenia.
Morin is one of the naturally occurring bioflavonoids,
originally isolated from members of the Moraceae family
[8], mostly found in different herbs and fruits including
onion, seed weeds, mill, fig, almond, red wine and Osage
orange [9,10]. Morin exhibited several pharmacological
properties such as antioxidant [11,12], anti-inflammatory
[13], chemo-protective [14], anticancer [15], and anti-
promotion [16]. Nandhakumar et al., [10] reported that,
morin supplementation to cancerous rats significantly
attenuated oxidative stress and brought the decreased of
SOD, CAT, and GPx activities to normal levels. Also,
morin has shown to protect various human cells, such
as myocytes, endothelial cells, hepatocytes and erythro-
cytes, against free radical induced oxidative damages
[17,18]. The chemical structure of morin and other bio-
flavonoids can be distinguished by the presence of two
aromatic rings connected by c-pyrone ring where polar
hydroxyl groups are bind at various positions. These hy-
droxyl groups are suggested to be responsible for the
free radical scavenging properties shared by morin and
other naturally occurring bioflavonoids [19]. Interest-
ingly, another bioflavonoid, quercetin, was found to
attenuate bone loss and osteopenia associated with ex-
perimentally induced diabetes in rodents [3]. One of the
main gratitude of morin is for its very minimal toxicity
even at higher dose usage [11,20]. Literature survey
revealed that morin has not been tested for its osteopro-
tective affects. Because of its high abilities against several
chronic and elderly diseases, this study is designed to
investigate the possible alleviating effects of morin on




The present study was conducted in eight weeks old male
Wister albino rats weighting 250–280 g were obtained
from the Experimental Animal Care Center, College of
Pharmacy, King Saud University, Riyadh, Saudi Arabia.
They were housed under controlled environmental condi-
tions (25°C and a 12 h light/dark cycle) and had free ac-
cess to pulverized standard rat pellet diet (Manufactured
by Grain Silos & Flour Mills Organization, Riyadh, Saudi
Arabia) and tap water. All experimental procedures in-
cluding euthanasia were conducted in accordance with
the National Institute of Health Guide for the Care and
Use of Laboratory Animals, Institute for Laboratory Ani-
mal Research (NIH Publications No. 80–23; 1996) as well
as the Ethical Guidelines of the Experimental Animal Care
Center, College of Pharmacy, King Saud University,
Riyadh, Saudi Arabia.Diabetes induction
Diabetes was chemically induced by intraperitoneal (i.p.)
injection of freshly prepared in 0.1 mol/L citrate buf-
fered solution (pH 4.5) of streptozotocin (Sigma Aldrich,
St. Louis, MO, USA) at a dose of 55 mg/kg body weight.
Control (vehicle) rats were injected with equal volume
of 0.1 mol/L citrate buffer. Four days after STZ injection,
diabetes induction was confirmed by measuring fasting
blood glucose level in a tail vein blood samples using
ACCU-CHEK compact plus glucometer (Roche, France).
Rats with glucose level of 300 mg/dl or higher were con-
sidered as diabetic.
Experimental design
Normal healthy rats were used as normal control and
diabetic-induced rats and were randomly divided into
four groups by taking six rats in each group: (1) Vehicle
treated normal rats (Cont), (2) STZ treated rats (STZ),
(3) STZ + morin (15 mg/kg/day) treated rats (STZ+M15)
and (4) STZ + morin (30 mg/kg/day) treated rats
(STZ+M30). Morin doses were selected from litera-
ture [19,21] and the treatment was started orally by gav-
age after a week of STZ injection and continued for five
consecutive weeks. General health and behavior of the ani-
mals were carefully monitored during the entire study. At
the end of the treatment, rats were fasted overnight and
under the slight anesthesia, blood samples were collected
through cardiac puncture in plain sterilized centrifuge
tubes. Blood samples were centrifuged at 4000 RPM for 10
minutes. Serum was suppurated and stored at −80°C till
analysis. Both the femoral bones were dissected immedi-
ately and preserved for micro CT analysis.
Assay of glucose and insulin levels
Serum glucose level were assayed using commercially
available kit (RANDOX Laboratories Ltd., UK), while in-
sulin serum level was assayed using ELISA kit (Bio-
Source, Europe S.A., Belgium).
Assay for bone metabolic biomarkers
Serum level of deoxypyridinoline cross links (DPD),
osteocalcin (OC), bone specific alkaline phosphatase
(BALP) and telopeptides of collagen type I (CTX) were
determined by using ELISA kits (USCN LIFE, Wuhan
EIAab Science Co., Ltd).
Assay for inflammatory cytokines levels
Concentrations of IL-1β, IL-6, and TNF-α were deter-
mined in serum using commercially available ELISA kits
(USCN LIFE, Wuhan EIAab Science Co., Ltd).
Assessment of systemic oxidative stress
In serum, thiobarbituric acid reactive substances (TBARS)
and reduced glutathione (GSH) levels were estimated
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stress. A TBARS assay kit (ZeptoMetrix Corporation,
Buffalo, New York, USA) was used to measure lipid per-
oxidation products, malondialdehyde (MDA) equivalents.
Briefly, 100 μl of serum was mixed with 2.5 ml reaction
buffer (provided by the kit) and heated at 95°C for 60 min.
After cooling, the supernatant’s absorbance was recorded
at 532 nm. Serum GSH levels were assayed by using the
method described by Sedlak and Lindsay (1968) [22]. In
brief, 0.5 mL serum was mixed with 0.2 M Tris buffer, pH
8.2 and 0.1 mL of 0.01 M Ellman's reagent, [5,5'-dithiobis-
(2-nitro-benzoic acid)] (DTNB). Sample tubes were then
centrifuged at 3000 RPM at room temperature for 15 min.
The absorbance of the clear supernatants was measured at
412 nm.
Micro-CT analysis
Trabecular bone mineral density (BMD) and other mor-
phometric parameters such as percent bone volume (BV/
TV), structure model index (SMI), trabecular number
(Tb.N), trabecular separation (Tb.Sp), trabecular thick-
ness (Tb.Th) and trabecular porosity (Tb.Po) were
measured in the right rat femoral bones head using a
high-resolution, cone-Beam micro CT system (SkyScan
1172, SkyScan, Kontich, Belgium) that was kindly pro-
vided by Engineer Abdullah Bagshan Growth Factors
Bone Regeneration Chair (GFBR), King Saud Univer-
sity, Riyadh, Saudi Arabia. In brief, bone samples were
placed in a cylindrical holder, where the longitudinal
axis of the bone and the sample holder were parallel to
each other. Scans were done using 70 kV applied volt-
age with one mm aluminum filter. All cross sections
contained 1024×1240 pixels with an isotropic voxel
size of 10 μm. Data analysis was carried out by CT
Analyzer 1.10.1.0 software (SkyScan, Kontich, Belgium).
Depending on the length of the specimen, high resolution
scanning was completed with slice number up to 1700.
All scanning conditions and reconstruction procedure
were those recommended by the manufacturer [23].
Statistical analysis
Data were expressed as means±S.E.M. Statistical analysis
was carried out using one-way ANOVA followed by
Newman-Keuls as post hoc test. P value of ≤ 0.05 was
considered statistically significant. All statistics tests were
conducted using Graph Pad Prism (version 5) software.
Results
Effects on body weight, blood glucose and insulin levels
Mean body weights are significantly (P<0.001) decreased
in diabetic rats as compared to control animals. Morin
treatments could not correct the body weights signifi-
cantly (Figure 1A). Fasting blood glucose levels were sig-
nificantly (P<0.001) increased and insulin levels weresignificantly (P<0.01) decreased in STZ group as com-
pared to control animals. In higher dose (30 mg/kg/day)
morin treated group, glucose levels were significantly
(P<0.05) reduced and insulin levels were significantly
(P<0.05) increased compared to untreated diabetic rats
(Figure 1B & C).
Micro-CT analysis
Experimentally-induced diabetes rats resulted impairment
in BMD significantly compared to control rats. In diabetic
group, there was a significant decrease in BV/TV, Tb.N
and Tb.Th (P<0.01, P<0.01, P<0.05 and P<0.01, respect-
ively) and increase in SMI, Tb.Sp and Tb.Po (P<0.01,
P<0.05 and P<0.05, respectively) as compared to control
group of animals. Morin treatment with higher taken dose
showed significant improvement in trabecular bone mass
loss and microarchitecture deterioration in diabetic rats.
BMD, BV/TV, Tb.N and Tb.Th values were significantly
(P<0.05) higher, and the values of Tb.Sp and Tb.Po were
significantly (P<0.05) lower in morin treated diabetic rats
(30 mg/kg) compared to untreated diabetic rats (Table 1).
As shown in the 3D micro CT image (Figure 2), the green
area justified the above Table 1 parameters and showed
morin protective effects on trabecular bone of the femur
head of normal and diabetic rats.
Effects on bone metabolic biomarkers
Serum levels of bone metabolic biomarkers including
DPD (Figure 3A), OC (Figure 3B), BALP (Figure 3C)
and CTX (Figure 3D) are significantly (P<0.05) increased as
compared to levels in control group. Morin treatment only
at higher dose (30 mg/kg/day) for 5 consecutive weeks to
diabetic rats showed significant inhibition in DPD (P<0.05),
OC (P<0.01) and BALP (P<0.05) biomarkers respectively.
Effects on serum IL-1β, IL-6 and TNF-α
In diabetic rats, serum IL-1β (Figure 4A), IL-6 (Figure 4B)
and TNF-α (Figure 4C) levels were significantly P<0.01,
P<0.05 and P<0.05 increased compared to control group
respectively. Higher taken dose of morin, significantly
(P<0.05) reduced the elevated interleukins and TNF-α
levels in comparison to untreated diabetic rats respectively.
Effects on systemic oxidative stress
Serum TBARS levels (Figure 5A) significantly (P<0.01)
increased while GSH (Figure 5B) decreased significantly
(P<0.05) in diabetic rats as compared to control animals.
Morin administration following higher dose significantly
(P<0.05) decreased the elevated TBARS levels and increased
the reduced GSH levels as compared to STZ group.
Discussion
Experimentally induced diabetes by streptozotocin (STZ)































































































Figure 1 Effects of morin on (A) animals final body weight, (B) blood glucose and (C) insulin levels. Data were expressed as Mean±S.
EM (n=6) and analyzed using one-way ANOVA followed by Student Newman-Keuls as post hoc test. ***a P<0.001 and **a P<0.01 Control vs
STZ group; *b P<0.05 STZ vs. STZ+M15 or STZ+M30 groups.
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investigations [24,25]. Intraperitoneal STZ injection to
the animals results in a prompt pancreatic β-cells destruc-
tion, diminish the insulin levels and induce significant
hyperglycemia [24]. Similar results are found in the
present study. Rats treated with morin (30 mg/kg/day) to
diabetic rats for a period of 5 weeks significantly decreased
the levels of glucose and increased insulin levels compared
to untreated diabetic rats. There is increasing evidence of
potential benefits of phenolic compounds in the cellular
regulations such as redox control and inflammatory
responses, and thus may protect against diabetes [26,27].
In addition, one in vivo study suggested that quercetin, a
phenolic compound, has a protective effect in diabetes
by decreasing oxidative stress and preserving pancreatic
β-cell integrity, possibly through decreasing lipid peroxi-
dation and nitric oxide production, as well as by increas-
ing antioxidant enzyme activities [28]. All of these studies
suggest that the application of phenolic compounds might
positively preserve β-cells and their function. In present
study, morin revealed hypoglycemic effect and also
enhanced the insulin sensitivity, this may suggest that,
morin has antidiabetic potentials.Table 1 Effects of morin on trabecular morphometric parame
Control STZ
BMD (g/cm3) 0.772±0.022 0.627±0.0
BV/TV (%) 0.444±0.021 0.277±0.0
SMI 0.874±0.101 1.655±0.1
Tb.N (mm-1) 3.534±0.143 2.515±0.1
Tb.Sp (mm) 0.173±0.011 0.224±0.0
Tb.Th (mm) 0.123±0.002 0.107±0.0
Tb.Po (%) 58.614±1.382 66.537±0.6
Data were expressed as Mean±S.EM (n=6) and analyzed using one-way ANOVA foll
Control vs STZ group; *b P<0.05 STZ vs. STZ+M15 or STZ+M30 groups.Hyperglycemia is suggested to be implicated in the devel-
opment of diverse diabetic complications, such as retinop-
athy, nephropathy, neuropathy, etc. [29]. Studies showed
that the resulted hyperglycemia is associated with impair-
ments in the micro-architecture of animal bones [25].
Thrailkill et al. reported that, hyperglycemia partially altered
micro-structure of trabecular and cortical bone [30]. In sev-
eral experimental studies done on different animals showed
that, STZ cause impairment in serum bone biomarkers
[3,31,32]. Likewise in the present study, sings of bone re-
sorption and inhibition of formation were observed and the
data revealed that the STZ injection significantly elevated
the bone biomarkers named DPD, OC, BALP and CTX. In
addition, micro CTanalysis showed a decrease in trabecular
BMD, BV/TV, Tb.N and Tb.Th and an increase in
SMI, Tb.Sp and Tb.Po in diabetic rats.
Various mechanisms have been suggested to be respon-
sible for the pathogenesis of diabetic-induced osteopenia.
One of the most widely accepted mechanisms is the oxida-
tive stress associated with hyperglycemia. Earlier studies
documented that hyperglycemia can trigger oxidative stress
resulting in alteration of bone metabolism and architecture









owed by Student Newman-Keuls as post hoc test. *a P<0.05 and **a P<0.01
Figure 2 3D micro CT image showing morin protective effects on trabecular bone (Green portion) of the femur head of normal and
diabetic rats.
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such as bone cells via generating free radical known as
ROS [2,4,5]. Both TBARS and GSH can be considered as
sensitive parameters for oxidative stress. TBARS is a
byproduct of lipid peroxidation process following free rad-
ical like ROS reaction with membrane lipids. On the other
hand, glutathione is an important intrinsic non-enzymatic
antioxidant. It is a free radical scavenger which maintains
cellular normal redox state and neutralizes all the deleteri-
ous effects of oxidative stress [10]. Increase in serum
TBARS level and decrease the GSH level, as showed in our




















































Figure 3 Effects of morin on serum levels of (A) DPD, (B) OC, (C) BALP
(n=6) and analyzed using one-way ANOVA followed by Student Newman-K
*b P<0.05 and **b P<0.01 STZ vs. STZ+M15 or STZ+M30 groups.stress. These finding are in agreement with other studies
where systemic oxidative stress was found to be associated
with experimentally induced diabetes [3,31]. In addition,
hyperglycemia itself can potentiate oxidative stress process.
High blood glucose level has been reported to trigger oxi-
dative stress process in many cell types under diabetic con-
ditions via both increased production of ROS and
decreased endogenous antioxidant capacity [34,35]. Inflam-
mation is another possible mechanism that might be
involved in bone loss associated with diabetes. Diabetic
conditions are well known to increase the level of inflam-






















































and (D) CTX in diabetic rats. Data were expressed as Mean±S.EM


















































































Figure 4 Effects of morin on serum levels of (A) IL-1β, (B) IL-6 and (C) TNF-α in diabetic rats. Data were expressed as Mean±S.EM (n=6)
and analyzed using one-way ANOVA followed by Student Newman-Keuls as post hoc test. *a P<0.05 and **a P<0.01 Control vs STZ group; *b
P<0.05 STZ vs. STZ+M15 or STZ+M30 groups.
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kines in the process of bone loss with or without diabetes
[7,31,38,39]. The process of the development and activa-
tion of bone resorping cells, osteoclasts, was found to be
strongly potentiated by these cytokines via binding to their
own specific receptors on the surface of the osteoclasts
[38]. Similarly in present study, IL-1β, IL-6 and TNF-α
level were significantly elevated in diabetic animals. We
suggest that the inflammatory conditions associated with
experimentally induced diabetes have activated the process
of osteoclastogenesis, which may explain the impairment
in bone metabolic markers noticed in our study.
Interest in the possible health benefits of flavonoids
has increased owing to their potent antioxidant and
free-radical scavenging activities observed in vivo and
in vitro studies. Morin is one of them and has been used
in herbal medicines and for food preservatives [40]. Sev-
eral biological properties have been suggested for morin,
including antioxidant and/or free radical scavenger prop-



































Figure 5 Effects of morin on serum levels of (A) TBARS and (B) GSH in
analyzed using one-way ANOVA followed by Student Newman-Keuls as po
STZ vs. STZ+M15 or STZ+M30 groups.hepatic tissues [41-43]. Flavonoids, in general, are now
well recognized to possess numerous pharmacological
activities, mainly through their ability to inhibit enzymes
and/or their antioxidant properties [44] and are powerful
free radical scavengers [45]. Epidemiologic studies ex-
ploring the role of flavonoids in human health for pro-
tecting with their abilities to cardiovascular disease,
cancer and diabetic-induce disorders such as neur-
opathy, retinopathy and osteopenia. Although few stud-
ies demonstrated no effects, and a few studies suggest
potential harm [46-48]. However, there are no reports
on morin toxicity in any of the preclinical and clinical
studies. Thus, the present pre-clinical study showing po-
tential on diabetic-induced osteopenia will be good an
opening to use morin for clinical trials. Interestingly,
some of these flavonoids were found to attenuate bone
loss and osteopenia associated with experimentally
induced diabetes in rodents. Liang et al. reported that,
quercetin can alleviate the diabetic induced impairment































diabetic rats. Data were expressed as Mean±S.EM (n=6) and
st hoc test. *a P<0.05 and **a P<0.01 Control vs STZ group; *b P<0.05
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[3]. Furthermore, using dual-energy X-ray absorpti-
ometry (DEXA), Pohaci et al. found that chronic admin-
istration of natural polyphenols can also ameliorates
diabetic induced alteration in BMD [49]. Similar results
were found in present study, as morin showed protective
effects against diabetic induced bone loss in rats. Morin,
especially at the higher dose, significantly attenuated the
increased levels of bone turn over biomarkers, DPD, OC
and BALP. In addition, the impaired values of trabecular
BMD, microarchitecture and morphometric parameters
were significantly corrected after morin administration
for 5 consecutive weeks to diabetic rats. The antioxidant,
anti-inflammatory and blood glucose lowering properties
of morin might explain its osteo-protective effects against
diabetic induced osteopenia in the current study. Morin is
a potent antioxidant, which was found to exert strong in-
hibitory effect on ROS generation [8]. It is also an effective
free radical scavenger [50]. Morin was reported to restore
the expression, activities of antioxidant enzymes and levels
of GSH [8]. Morin significantly attenuated oxidative stress
and brought the decreased of SOD, CAT, and GPx activ-
ities and the increased levels of TBARS and hydroperox-
ides to near normal values in rats were having mammary
carcinoma [10]. However, morin has that antioxidant
property was shown to protect various human cells, such
as myocytes, endothelial cells, hepatocytes and erythro-
cytes, against oxidative damages [17,18]. The hydroxyl
groups present at the C-3 and C-5, besides at C-4 are sug-
gested to be responsible for morin beneficial properties
and is considered contributory for its antioxidant activity
via quenching free radicals generated during oxidative
stress conditions [51]. Both the doses of morin in present
study, significantly inhibited TBARS elevated levels, while
only the higher dose restored GSH reduced level in dia-
betic rats. In addition, morin higher dose significantly low-
ered the level of blood glucose after 5 weeks of treatment
in diabetic rats. This may result of inhibition in systemic
oxidative stress because hyperglycemia has been recog-
nized to trigger oxidative stress and to be involved in the
pathogenesis of osteopenia in association of diabetes [3,4].
The anti-inflammatory properties of morin were reported
in several in vitro and in vivo studies [52-54] and it was
found to have beneficial effects on inflammatory diseases
such as colitis in rats [52,55]. Recently, Chen and his col-
leagues reported that, morin suppressed the production
and expression of several inflammatory mediators includ-
ing NO, PGE-2, iNOS and COX-2 [56]. Similarly, the
results in present study revealed the potentials of morin
(30 mg/kg) against elevation of inflammatory cytokines
IL-1β, IL-6 and TNF-α in diabetic animals, which sup-
ports its anti-inflammatory property and also its possible
beneficial effects in diseases where inflammation is
deemed to play a pathological role.In conclusion, our results revealed the positive effect
of morin against diabetic associated impairment in bone
metabolism, density and architecture in rats. Such osteo-
protective effects might be explained through direct or
indirect ways of its potent anti-inflammatory and anti-
oxidant capabilities to lower bone loss involved by the dia-
betic conditions. Although, the osteo-protective properties
of morin against diabetic induce osteopenia were identi-
fied in this study, the mechanisms underlying the effect of
morin on oxidative stress and inflammation under diabetic
condition still need to be identified in future studies.
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